1156 related articles for article (PubMed ID: 31478503)
1. Antibody-drug conjugates for cancer.
Chau CH; Steeg PS; Figg WD
Lancet; 2019 Aug; 394(10200):793-804. PubMed ID: 31478503
[TBL] [Abstract][Full Text] [Related]
2. Antibody-Drug Conjugates as Cancer Therapeutics: Past, Present, and Future.
Vezina HE; Cotreau M; Han TH; Gupta M
J Clin Pharmacol; 2017 Oct; 57 Suppl 10():S11-S25. PubMed ID: 28921650
[TBL] [Abstract][Full Text] [Related]
3. Preclinical Pharmacokinetic Considerations for the Development of Antibody Drug Conjugates.
Kamath AV; Iyer S
Pharm Res; 2015 Nov; 32(11):3470-9. PubMed ID: 25446773
[TBL] [Abstract][Full Text] [Related]
4. The Latest Research and Development into the Antibody-Drug Conjugate, [fam-] Trastuzumab Deruxtecan (DS-8201a), for HER2 Cancer Therapy.
Nakada T; Sugihara K; Jikoh T; Abe Y; Agatsuma T
Chem Pharm Bull (Tokyo); 2019; 67(3):173-185. PubMed ID: 30827997
[TBL] [Abstract][Full Text] [Related]
5. Antibody-Drug Conjugate-Based Therapeutics: State of the Science.
Birrer MJ; Moore KN; Betella I; Bates RC
J Natl Cancer Inst; 2019 Jun; 111(6):538-549. PubMed ID: 30859213
[TBL] [Abstract][Full Text] [Related]
6. Exposure-Efficacy Analysis of Antibody-Drug Conjugates Delivering an Excessive Level of Payload to Tissues.
Zhang D; Dragovich PS; Yu SF; Ma Y; Pillow TH; Sadowsky JD; Su D; Wang W; Polson A; Khojasteh SC; Hop CECA
Drug Metab Dispos; 2019 Oct; 47(10):1146-1155. PubMed ID: 31358513
[TBL] [Abstract][Full Text] [Related]
7. Antibody-drug conjugates for previously treated aggressive lymphomas: focus on polatuzumab vedotin.
Burke JM; Morschhauser F; Andorsky D; Lee C; Sharman JP
Expert Rev Clin Pharmacol; 2020 Oct; 13(10):1073-1083. PubMed ID: 32985934
[TBL] [Abstract][Full Text] [Related]
8. Antibody-drug conjugates: recent advances in conjugation and linker chemistries.
Tsuchikama K; An Z
Protein Cell; 2018 Jan; 9(1):33-46. PubMed ID: 27743348
[TBL] [Abstract][Full Text] [Related]
9. Factors influencing the choice of monoclonal antibodies for antibody-drug conjugates.
Hasan MM; Laws M; Jin P; Rahman KM
Drug Discov Today; 2022 Jan; 27(1):354-361. PubMed ID: 34597756
[TBL] [Abstract][Full Text] [Related]
10. Investigational Antibody-Drug Conjugates for Treatment of B-lineage Malignancies.
Herrera AF; Molina A
Clin Lymphoma Myeloma Leuk; 2018 Jul; 18(7):452-468.e4. PubMed ID: 29804872
[TBL] [Abstract][Full Text] [Related]
11. Antibody-Drug Conjugates for Cancer Therapy.
Hafeez U; Parakh S; Gan HK; Scott AM
Molecules; 2020 Oct; 25(20):. PubMed ID: 33081383
[TBL] [Abstract][Full Text] [Related]
12. Antibody-drug conjugates: Principles and opportunities.
Phuna ZX; Kumar PA; Haroun E; Dutta D; Lim SH
Life Sci; 2024 Jun; 347():122676. PubMed ID: 38688384
[TBL] [Abstract][Full Text] [Related]
13. Antibody drug conjugates under investigation in phase I and phase II clinical trials for gastrointestinal cancer.
Leal AD; Krishnamurthy A; Head L; Messersmith WA
Expert Opin Investig Drugs; 2018 Nov; 27(11):901-916. PubMed ID: 30359534
[TBL] [Abstract][Full Text] [Related]
14. Antibody-Drug Conjugates for Breast Cancer.
Marmé F
Oncol Res Treat; 2022; 45(1-2):26-36. PubMed ID: 34915488
[TBL] [Abstract][Full Text] [Related]
15. Clinical pharmacology strategies in supporting drug development and approval of antibody-drug conjugates in oncology.
Liu SN; Li C
Cancer Chemother Pharmacol; 2021 Jun; 87(6):743-765. PubMed ID: 33792763
[TBL] [Abstract][Full Text] [Related]
16. The target invites a foe: antibody-drug conjugates in gynecologic oncology.
Campos MP; Konecny GE
Curr Opin Obstet Gynecol; 2018 Feb; 30(1):44-50. PubMed ID: 29227302
[TBL] [Abstract][Full Text] [Related]
17. Antibody drug conjugates as targeted cancer therapy: past development, present challenges and future opportunities.
Maiti R; Patel B; Patel N; Patel M; Patel A; Dhanesha N
Arch Pharm Res; 2023 May; 46(5):361-388. PubMed ID: 37071273
[TBL] [Abstract][Full Text] [Related]
18. Benefits and challenges of antibody drug conjugates as novel form of chemotherapy.
Fatima SW; Khare SK
J Control Release; 2022 Jan; 341():555-565. PubMed ID: 34906604
[TBL] [Abstract][Full Text] [Related]
19. Unlocking the potential of antibody-drug conjugates for cancer therapy.
Drago JZ; Modi S; Chandarlapaty S
Nat Rev Clin Oncol; 2021 Jun; 18(6):327-344. PubMed ID: 33558752
[TBL] [Abstract][Full Text] [Related]
20. Site-Specific Conjugation of the Indolinobenzodiazepine DGN549 to Antibodies Affords Antibody-Drug Conjugates with an Improved Therapeutic Index as Compared with Lysine Conjugation.
Bai C; Reid EE; Wilhelm A; Shizuka M; Maloney EK; Laleau R; Harvey L; Archer KE; Vitharana D; Adams S; Kovtun Y; Miller ML; Chari R; Keating TA; Yoder NC
Bioconjug Chem; 2020 Jan; 31(1):93-103. PubMed ID: 31747250
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
